Naomi Campbell tells war crimes court was given diamonds
THE HAGUE (Reuters) – British supermodel Naomi Campbell, testifying at the war crimes trial of former Liberian President Charles Taylor, said on Thursday she had been given a pouch containing diamonds while in South Africa in 1997.
“I saw a few stones, they were very small, dirty looking stones,” she told the U.N. Special Court for Sierra Leone in The Hague, but added she was not sure who the diamonds were from.
Campbell tells war crimes court was given diamonds
THE HAGUE (Reuters) – British supermodel Naomi Campbell, testifying at the war crimes trial of former Liberian President Charles Taylor, said on Thursday she had been given a pouch containing diamonds while in South Africa in 1997.
“I saw a few stones, they were very small, dirty looking stones,” she told the U.N. Special Court for Sierra Leone in The Hague, but added she was not sure who the diamonds were from.
Campbell gives “blood diamond” testimony
AMSTERDAM (Reuters) – Naomi Campbell testifies on Thursday about a “blood diamond” at the war crimes trial of former Liberian leader Charles Taylor, who prosecutors say gave such a gem to the British supermodel.
The prosecution at the Special Court for Sierra Leone summoned Campbell to back their allegations that Taylor, 62, received diamonds from rebels in Sierra Leone, which they say he then used to buy weapons during a 1997 trip to South Africa.
Campbell gives “blood diamond” testimony at Taylor trial
AMSTERDAM (Reuters) – Naomi Campbell testifies on Thursday about a “blood diamond” at the war crimes trial of former Liberian leader Charles Taylor, who prosecutors say gave such a gem to the British supermodel.
The prosecution at the Special Court for Sierra Leone summoned Campbell to back their allegations that Taylor received diamonds from rebels in Sierra Leone, which they say he then used to buy weapons during a 1997 trip to South Africa.
DSM raises 2010 outlook as Q2 tops estimates
AMSTERDAM, August 3 (Reuters) – Dutch chemicals group DSM
(DSMN.AS: Quote, Profile, Research, Stock Buzz), increasingly focused on life sciences, raised its
full-year outlook and said it did not expect a double-dip
recession after second-quarter profit beat expectations.
DSM said 2010 would be a “strong year”, an improvement on
its previous forecast of a “good year”, although it added the
recovery could slow down on the back of macroeconomic
uncertainty and a potential disruption to financial markets.
European chemicals post strong Q2 on volume gains
FRANKFURT/AMSTERDAM, July 29 (Reuters) – European chemicals
companies mostly posted strong quarterly results on Thursday,
after volume growth continued to firm, boosting hopes for
sustained sector gains in the face of economic headwinds.
The improved second-quarter volumes continued a trend of
rising demand seen in recent months after an unprecedented
downturn at the start of 2009, when recession fully set in, and
added to evidence chemical makers are out of the woods.
AkzoNobel Q2 to benefit from cost cuts, demand uptick
AMSTERDAM, July 22 (Reuters) – Margins at Dutch chemicals
company AkzoNobel (AKZO.AS: Quote, Profile, Research, Stock Buzz) will again be in focus on Friday
when the firm is seen reporting an 11 percent rise in second
quarter core profit on cost cuts and improving paints demand.
The world’s largest paints maker is seen reporting earnings
before interest, taxes, depreciation and amortisation (EBITDA)
excluding incidentals of 563 million euros according to the
average forecast from a Reuters poll. [ID:nLDE66J1EW]
A familiar name picks up coverage of Gannett
For those following Gannett Co. second quarter earnings on Friday, a familiar name might be popping in on the line. Douglas Arthur — the sharp analyst late of Morgan Stanley known for such hits as “Knight Ridder: A Scenario Analysis”– is back covering the sector again. Or something akin to it.
Arthur initiated coverage of Gannett for Evercore Partners last week, stamping Gannett with an “overweight” rating and a price target of $18. It’s likely his report sent shares in the newspaper and broadcasting company soaring about 6% to$14.16 on July 7 close.
Pharming signs manufacturing deal with Sanofi-Aventis
AMSTERDAM, July 6 (Reuters) – Dutch biotech firm Pharming
(PHAR.AS: Quote, Profile, Research) inked a deal with Sanofi-Aventis (SASY.PA: Quote, Profile, Research) to increase
production capacity of its drug Ruconest, as its quest to
produce medicines from genetically modified animals inches
closer.
A European Medicines Agency (EMA) committee recommended last
month granting marketing approval to Ruconest, made from rabbit
milk, in a key move for Pharming which has struggled financially
after regulatory setbacks.
Spyker avoids more debt in final Saab payment
AMSTERDAM (Reuters) – Dutch carmaker Spyker Cars (SPYKR.AS: Quote, Profile, Research, Stock Buzz) used internal funding rather than external debt to pay General Motors GM.UL the final $24 million purchase price for Sweden’s Saab, ending concern over how it would foot the bill.
Niche carmaker Spyker, which has never made a profit, took over the larger Saab from GM earlier this year and is now working to revive the flagging brand, but the final installment of the purchase price had been due on July 15.
-
Follow Aaron
